Alleima (ALLEI) Company presentation summary
Event summary combining transcript, slides, and related documents.
Company presentation summary
1 Jun, 2026Market position and business overview
Leading provider of advanced stainless steels, special alloys, ultrafine medical wires, and industrial heating products with strong positions in niche markets.
Operates a fully integrated value chain with industry-leading R&D and global reach, including 5 R&D centers and 40+ sales offices.
Premium offering structured across three divisions: Tube, Kanthal, and Strip, each holding top market positions in their segments.
Serves demanding industries such as oil & gas, industrial, medical, chemical, and nuclear, with diversified revenue streams.
Financial performance and targets
FY 2025 revenues reached SEK 18,630 million, with adjusted EBIT of SEK 1,555 million and an 8.3% margin.
Organic revenue growth was flat for the year, with free operating cash flow at SEK 1,100 million.
Proposed dividend of SEK 2.50 per share, representing 71% of profit for the period (adjusted for metal price effects).
Maintains a net debt to equity ratio below 0.3x and an average adjusted EBIT margin target above 9% over the cycle.
Segment performance
Tube division faced high market uncertainty, with organic order intake down 7% and revenue down 11%; EBIT margin at 8.4%.
Kanthal division saw positive topline growth, with organic order intake up 9% and revenue up 10%; EBIT margin at 16.3%.
Strip division reported organic order intake down 11% but revenue up 20%, with improved EBIT margin at 9.5%.
Latest events from Alleima
- Strong niche market positions, resilient earnings, and sustainability drive growth ambitions.ALLEI
Company presentation1 Jun 2026 - Order intake and revenues declined amid uncertainty, but key segments and balance sheet remained resilient.ALLEI
Q1 202627 Apr 2026 - Flat organic growth, strong cash flow, and improved EBIT amid robust market sentiment.ALLEI
Q2 20243 Feb 2026 - Flat 2025 revenue, strong cash flow, and SEK 2.50 dividend amid FX and market headwinds.ALLEI
Q4 20252 Feb 2026 - Organic revenue up 3%, EBIT margin 7%, with strong nuclear and medical investments.ALLEI
Q3 202419 Jan 2026 - Stable earnings, strong cash, and growth in key segments despite mixed market demand.ALLEI
Q4 20249 Jan 2026 - Strong Q1 growth and margins, but Q2 faces currency and metal price headwinds.ALLEI
Q1 202528 Dec 2025 - Profitability held up despite revenue declines and market uncertainty, with resilient margins.ALLEI
Q2 202516 Nov 2025 - Profitable growth, innovation, and sustainability drive expansion in high-value segments.ALLEI
CMD 20258 Nov 2025